Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study
Abstract
Background We conducted a survey to investigate the prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy. Methods In total, 130 eligible patients completed the Self-Rating Anxiety Scale and Self-Rating Depression Scale at week 4 after CAR-T cell infusion. We collected sociodemographic information during the same period. We studied factors associated with anxiety and depressive symptoms using logistic regression analysis. Results The prevalence of anxiety and depressive symptoms at week 4 after infusion were 13.8% and 40.0%, respectively. A cutoff value of 50 or above indicates significantly anxiety and depressive symptoms. Binary logistic regression analysis showed that high school education and above (OR = 0.22, 95% CI = 0.06-0.78) and middle age (OR = 0.16, 95% CI = 0.03-0.90) were associated with lower risk of anxiety symptoms, and increased odds of depressive symptoms was associated with old age (OR = 11.39, 95% CI = 2.50-51.88), non-manual occupations before illness (OR = 3.72, 95% CI = 1.20-11.58), and higher healthcare expenditure (OR = 3.93, 95% CI = 1.50-10.33), while lower risk of depressive symptoms was associated with rural household location (OR = 0.25, 95% CI = 0.08-0.76) and being cared for by spouse (OR = 0.12, 95% CI = 0.02-0.63). Conclusions Patients receiving CAR-T therapy with lower education background, old ages, urban house…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the identified study, patients during hospitalization after CAR-T administration had a high prevalence of depression symptoms, around 40%.
“En esta investigación los autores observaron que los pacientes durante el periodo de hospitalización tras la administración del tratamiento presentaban una elevada prevalencia de síntomas de depresión, situada en torno al 40%.”
From Programa de inoculación de estrés para el manejo del malestar emocional asociado a la terapia de células CAR-T: caso clínico. (2023) · cites this paper as [9]
There is currently scarce literature on the psychological characteristics associated with CAR-T cell treatment.
“existe una escasa literatura sobre las características psicológicas asociadas al tratamiento de células CAR-T (9)”
From Programa de inoculación de estrés para el manejo del malestar emocional asociado a la terapia de células CAR-T: caso clínico. (2023) · cites this paper as [9]
Cites
Nipp, R. D., El‐Jawahri, A., Moran, S. M., D'Arpino, S. M., Johnson, P. C., Lage, D. E., Wong, R. L., Pirl, W. F., Traeger, L., Lennes, I. T., et al. (2017) · Cancer · doi:10.1002/cncr.30912 · Cited by 230 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dhawale, T. M., Johnson, P. C., Gaballa, M., Nelson, A. M., Lavoie, M. W., Boateng, K. Y., Greydanus, C., Frigault, M. J., & El-Jawahri, A. R. (2022) · Cancer · doi:10.1002/cncr.34557 · Cited by 35 · see citing works
“Recent studies have highlighted the prevalence of psychological distress in this patient population.(38,39) Interestingly, the extent of psychological distress at the time of admission for CAR T‐cell therapy was similar in patients with lymphoma or leukemia and those with multiple myeloma.”
BackgroundTao, F., Xu, M.-N., Zou, Q., Tang, L., Feng, J., & Li, Z.-Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1080413 · Cited by 28 · see citing works
Self-citationNeurologic Complications of Cancer Immunotherapy
Alsalem, A., Scarffe, L., Briemberg, H., Aaroe, A., & Harrison, R. (2023) · Current Oncology · doi:10.3390/curroncol30060440 · Cited by 12 · see citing works
“Depression and anxiety have been reported in patients who have recovered from neurotoxicity, particularly older patients with less psychosocial support [118].”
BackgroundDepression in patients with hematologic malignancies: The current landscape and future directions.
Kuczmarski, T., Roemer, L., & Odejide, O. (2024) · Blood reviews · doi:10.1016/j.blre.2024.101182 · Cited by 11 · see citing works
Dai, H.-Y., Xu, S., Wang, Z.-X., Li, Z.-Y., Cao, J., Hu, T., & Zhou, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-02720-6 · Cited by 10 · see citing works
“Our prior research demonstrated that CAR-T patients experienced compromised mental well-being during their hospitalization post-treatment, with depressive symptoms being particularly severe 19 .”
Self-citationRemission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?
Perthus, A., Colin, F., Charton, E., Anota, A., Lhomme, F., Manson, G., de Guibert, S., Daufresne, P., Bellec, A., Bars, L. L., et al. (2024) · HemaSphere · doi:10.1002/hem3.72 · Cited by 8 · see citing works
Khatsuria, F., McMullan, C., Aiyegbusi, O., Shaw, K. L., Iqbal, R., Kinsella, F., Wilson, K., Pyatt, L., Lewis, M., Wheldon, S. M. R., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00256-0 · Cited by 7 · see citing works
Symptoms of Hematologic Tumors Patients after CAR-T Therapy: a Systematic Review and Meta-Analysis.
Sun, W., Wang, S., Han, J., Zhuo, L., Cao, J., & Zhou, F. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.11.002 · Cited by 2
Self-citationWu, J., Li, D., Mei, H., & Hu, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117949 · Cited by 1 · see citing works
Montoro-Lorite, M., García, G., Moreno-García, C., Domènech, A., Ayora, P., & Ramos, C. (2025) · Enfermería Clínica · doi:10.1016/j.enfcli.2024.502188 · Cited by 1 · see citing works
Sanz Cortés, A. (2023) · Psicooncologia · doi:10.5209/psic.91523
Quality of Life in CAR-T Cell Therapy
Alati, C., Pitea, M., Porto, G., Policastro, G., Bilardi, E., Utano, G., Giordano, L., Sgarlata, A., Delfino, I., Idato, A., et al. (2026) · Hematology Reports · doi:10.3390/hematolrep18030040
“Depression rates are similar between groups at one year [72,78–80].”
Liu, J., Liang, P.-P., Wang, Y., Huang, H., Zhang, S.-Z., Li, G.-Y., & Wu, H.-Y. (2026) · Medicine · doi:10.1097/md.0000000000048110
Feng, A., Gottam, M., Santivasi, W., & Leblanc, T. W. (2025) · Expert review of pharmacoeconomics & outcomes research · doi:10.1080/14737167.2025.2572317
- Authors
- Dai, H., Xu, S., Han, J., Li, Z., Cao, J., Hu, T., Li, H., Wei, J., Dou, X., Zhou, F., & Zheng, J.
- Affiliations
- Xuzhou Medical College (CN)
- Corresponding author
- Zhou, Fang
- Zheng, Junnian
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 286
- Pages
- 33-39
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W3130449359
- Cited by
- 16
- References
- 0
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 1
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Affective Disorders (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Graduate Research and Innovation Projects of Jiangsu Province
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Keywords
- anxiety symptoms, depressive symptoms, CAR T-cell therapy, hematologic malignancies, risk factors, educational attainment, age, occupation, health care expenditure, rural residence, spousal caregiving, psychological support
- MeSH terms
- Receptors, Chimeric Antigen, Anxiety, Cross-Sectional Studies, Depression, Humans, Middle Aged, Surveys and Questionnaires, T-Lymphocytes, Prevalence, Immunotherapy, Adoptive, Hematologic Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
